N-of-1 trials in cancer drug development
The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. In that regard, N-of-1 studies emerge as a potential addition to the drug development arsenal, although there are seve...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
1 June 2023
|
| In: |
Cancer discovery
Year: 2023, Volume: 13, Issue: 6, Pages: 1301-1309 |
| ISSN: | 2159-8290 |
| DOI: | 10.1158/2159-8290.CD-22-1377 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/2159-8290.CD-22-1377
|
| Author Notes: | Mohamed A. Gouda, Lars Buschhorn, Andreas Schneeweiss, Adam Wahida, and Vivek Subbiah |
| Summary: | The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. In that regard, N-of-1 studies emerge as a potential addition to the drug development arsenal, although there are several considerations before its broad application becomes feasible. In essence, N-of-1 trials are a departure from the traditional “drug-centric” model to a “patient-centric” model. Herein, we review the concept of N-of-1 trials and provide real-world examples of their use in the developmental therapeutics field. N-of-1 trials offer an exceptional opportunity for fast-tracking of cancer drug development in the precision oncology era. |
|---|---|
| Item Description: | Gesehen am 24.07.2023 |
| Physical Description: | Online Resource |
| ISSN: | 2159-8290 |
| DOI: | 10.1158/2159-8290.CD-22-1377 |